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PGC-1α dictates endothelial 
function through regulation of 
eNOS expression
Siobhan M. Craige1,*, Swenja Kröller-Schön2,*, Chunying Li1, Shashi Kant1, Shenghe Cai1, 
Kai Chen2,3, Mayur M. Contractor1, Yongmei Pei1, Eberhard Schulz2,* & John F. Keaney Jr.1,*
Endothelial dysfunction is a characteristic of many vascular related diseases such as hypertension. 
Peroxisome proliferator activated receptor gamma, coactivator 1α (PGC-1α) is a unique stress sensor 
that largely acts to promote adaptive responses. Therefore, we sought to define the role of endothelial 
PGC-1α in vascular function using mice with endothelial specific loss of function (PGC-1α EC KO) 
and endothelial specific gain of function (PGC-1α EC TG). Here we report that endothelial PGC-1α is 
suppressed in angiotensin-II (ATII)-induced hypertension. Deletion of endothelial PGC-1α sensitized 
mice to endothelial dysfunction and hypertension in response to ATII, whereas PGC-1α EC TG mice 
were protected. Mechanistically, PGC-1α promotes eNOS expression and activity, which is necessary 
for protection from ATII-induced dysfunction as mice either treated with an eNOS inhibitor (LNAME) 
or lacking eNOS were no longer responsive to transgenic endothelial PGC-1α expression. Finally, 
we determined that the orphan nuclear receptor, estrogen related receptor α (ERRα) is required to 
coordinate the PGC-1α -induced eNOS expression. In conclusion, endothelial PGC-1α expression 
protects from vascular dysfunction by promoting NO• bioactivity through ERRα induced expression of 
eNOS.
Hypertension is the most prevalent risk factor for vascular disease worldwide, with expectations that this con-
dition will impact up to 1.56 billion people by the year 20251. Patients with hypertension are at increased risk of 
heart attack and stroke, two major sources of cardiovascular morbidity and mortality. Among the sequelae of 
hypertension, endothelial dysfunction, characterized by compromised nitric oxide (NO• ) bioavailability2,3, is par-
ticularly prominent. Indeed, endothelial dysfunction has proven a powerful predictor of cardiovascular events4. 
Thus, there is considerable interest in developing strategies to improve endothelial function and NO• bioactivity 
as a means to ameliorate the consequences of hypertension, including cardiovascular disease.
Metabolic pathways have garnered increasing attention as being relevant to vascular disease. In this regard, 
caloric restriction and exercise – two conditions that alter the balance between energy storage and utilization, 
have emerged as strategies to mitigate chronic disease states, such as hypertension and its impact on the vascu-
lature. Both caloric restriction and exercise activate the energy-sensitive enzyme, AMP-activated protein kinase 
(AMPK), that can limit the development of endothelial dysfunction through decreased vascular reactive oxygen 
species (ROS) and improved NO• bioavailability5. One important downstream target of AMPK is peroxisome 
proliferator activated receptor gamma, coactivator 1α (PGC-1α )6, a transcriptional coactivator important for 
the regulation of both mitochondrial and cellular genes involved in metabolism and stress adaptation7,8. PGC-1α 
expression is decreased in aging9 and may be important for the aging associated decline of vascular function10. 
In vitro, endothelial PGC-1α demonstrates improved ROS detoxification and enhanced endothelial resistance 
to cellular injury11,12. However, the role of PGC-1α on the endothelium in vivo is not yet clear. Thus, we probed 
the impact of endothelial specific PGC-1α manipulation on mouse models of endothelial dysfunction and 
hypertension.
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Results
Loss of endothelial PGC-1α impairs endothelial NO• bioactivity. Previously we have demonstrated 
that the endothelium is modulated by mediators of mitochondrial function such as AMP kinase5 and uncoupling 
protein-213. As PGC-1α is well-established to mediate mitochondrial biogenesis and metabolic stress adaptation 
in other cell types6, we examined PGC-1α expression in endothelial cells from wild-type (WT) mice treated with 
a pressor dose (i.e, a dose known to induce endothelial dysfunction in WT mice) of angiotensin II (ATII). We 
observed a significant decrease in endothelial PGC-1α expression (Fig. 1A). These data suggest that suppression 
of endothelial PGC-1α expression may be important in promoting endothelial dysfunction in response to ATII.
To examine if loss of endothelial PGC-1α primes the endothelium for dysfunction, we created 
endothelial-specific loss of function (PGC-1α EC KO) mice which demonstrated a significant reduction in 
PGC-1α expression (Supplementary Figure 1A and B). We then examined endothelial function in response to 
ATII at a subpressor dose (i.e, a dose that does not significantly compromise endothelial function in WT mice). 
We found that loss of endothelial PGC-1α significantly sensitized the endothelium to dysfunction induced by 
ATII (Fig. 1B). Similarly, tissue NO• abundance (Fig. 1C) and eNOS expression (Supplementary Figure 1B and 1
C) was decreased in the PGC-1α EC KO mice treated with ATII. Tissue cGMP, a downstream read out of bioac-
tive NO• , was attenuated in the PGC-1α EC KO mice (Fig. 1D). In addition, endothelial cells from PGC-1α EC 
KO mice exhibited decreased eNOS mRNA (Fig. 1E) and protein (Fig. 1F) expression. These data suggest that loss 
of PGC-1α leads to compromised endothelial function, through decreases in eNOS expression and NO• bioac-
tivity. Finally, we tested a pressor ATII dose (Fig. 1G) and found that the PGC-1α EC KO mice had significantly 
increased blood pressure compared to the Cre control mice.
Figure 1. Loss of endothelial PGC-1α leads to reduced NO• bioactivity. (A) WT mice received a pressor 
dose of Angiotensin II (ATII; 1 mg/kg; 7 days). Mouse lung endothelial cells (MLECs) were harvested and 
PGC-1α mRNA expression measured (N = 4/group, *P < 0.05 vs. saline). Endothelial specific PGC-1α knock 
out (PGC-1α EC KO) mice and control EC Cre+ mice (Cre) were treated with a subpressor dose of ATII  
(0. 5 mg/kg; 7 days) and endothelial function estimated as (B) aortic isometric force in response to acetylcholine 
(Ach; N = 10–15/group, *P < 0.05 vs. Cre without ATII), (C) vessel NO• levels (N = 6/group, *P < 0.05 vs. Cre 
Ctl) and (D) tissue cGMP levels (N = 12/group *P < 0.05 vs. Cre Ctl). MLECs harvested from PGC-1α EC KO 
mice were used to measure eNOS (E) mRNA (N = 4–6/group, *P < 0.05 vs. Cre) or (F) protein (N = 3/group) 
expression. (G) Cre and PGC-1α EC KO mice were treated with a pressor dose of ATII (as in A) and systolic 
blood pressure was recorded (N = 4–8/group; *P < 0.05 vs Cre Ctl; $P < 0.05 vs Cre ATII; #P < 0.05 vs PGC-1α 
EC KO Ctl). Numbers below immunoblots represent densitometry relative to actin.
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Endothelial PGC-1α protects from angiotensin II-induced hypertension and dysfunction in vivo. 
To determine if upregulation of endothelial PGC-1α impacts NO• bioactivity, we created transgenic mice 
with constitutive human PGC-1α expression under the control of the vascular endothelial cadherin promoter 
(PGC-1α EC TG; Fig. 2A). These mice demonstrated increased endothelial PGC-1α expression (Fig. 2B and C). 
After a pressor dose of ATII, relaxation in response to acetylcholine (Ach) was attenuated in WT aorta, but largely 
preserved in vessels from PGC-1α EC TG mice (Fig. 2D). Similarly, NO• bioactivity after ATII treatment was pre-
served in PGC-1α EC TG mice as demonstrated by aortic tissue cGMP levels (Fig. 2E). We then tested the impact 
of preserved endothelial NO• bioactivity on ATII-induced hypertension. In WT mice, ATII infusion caused a 
significant increase in blood pressure as previously reported (Fig. 2F)14. This increase was prevented in PGC-1α 
EC TG mice (Fig. 2F). Together, these data confirm that augmentation of endothelial PGC-1α expression in vivo 
results in protection from endothelial dysfunction.
PGC-1α expression protects the endothelium through enhanced eNOS expression and 
NO• bioactivity. It is known in vitro that PGC-1α can protect the endothelium from ROS-induced dam-
age11,12. However, the impact of PGC1α on endothelial NO• generation is not known in vivo. Thus, we sought 
Figure 2. Endothelial PGC-1α overexpression protects from endothelial dysfunction. (A) PGC-1α 
endothelial specific transgene construct with representative expression of human (h) and mouse (m) PGC-1α 
mRNA in MLECs from the indicated genotype. (B) MLEC mRNA quantification (N = 3, *P < 0.05) (C) 
MLEC PGC-1α protein expression from the indicated mouse genotype. WT and PGC-1α EC TG mice were 
infused with a pressor dose of ATII (1 mg/kg; 7 days) for 7 days and examined for: (D) Aortic relaxation to Ach 
(N = 7–10/group; *P < 0.05 vs. WT + ATII), (E) cGMP content in aortic segments (N = 4/group; *P < 0.05 vs. 
WT Ctl) and (F) blood pressure of WT and PGC-1α EC TG mice treated with ATII (N = 9–11/group; *P < 0.05 
vs WT Ctl).
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to determine if PGC-1α overexpression influences NO• production and eNOS expression. In human aortic 
endothelial cells (HAECs), forced adenoviral overexpression of PGC-1α (Ad- PGC-1α ) was associated with 
enhanced NO• bioactivity assessed through cGMP production (Fig. 3A) coincident with a significant increase 
in eNOS mRNA (Fig. 3B) and protein expression (Fig. 3C and D). We observed a modest increase in phospho-
rylated eNOS (Ser1177), likely due to the total eNOS increase (Fig. 3D). Consistent with these findings, there 
was increased eNOS expression in endothelial cells from the PGC-1α EC TG mice (Fig. 3E). Aortic segments 
from PGC-1α EC TG mice exhibited reduced constriction in response to phenylephrine (Fig. 3F), consistent 
with increased basal NO• bioactivity. This response was specific to eNOS as it was abrogated by the eNOS inhib-
itor, L-Nitroarginine Methyl Ester (LNAME; 300 μ M; Fig. 3G). We examined the ability of endothelial PGC-1α 
expression to prevent ATII - induced hypertension in a prospective study where the WT and PGC-1α EC TG 
cohorts were administered LNAME (0.5 g/L) in the drinking water for 7 days followed by 7 days of LNAME + 
ATII. Results from this experiment demonstrated that eNOS was necessary for PGC-1α protection from hyper-
tension (Fig. 3H). The requirement for eNOS was further tested by breeding the PGC-1α EC TG mice onto the 
eNOS-null background (eNOS−/−). Endothelial nitric oxide synthase null mice are spontaneously hypertensive 
and exhibit endothelial dysfunction15. In these mice, the endothelial specific expression of PGC-1α was not pro-
tective from spontaneous hypertension (Fig. 3I). These data confirm that eNOS is a key contributor in mediating 
PGC-1α protection of the endothelium.
PGC-1α promotes eNOS expression through ERRα. One common mechanism of eNOS activa-
tion and upregulation is via the serine/threonine kinase, Akt16,17, therefore, we examined Akt expression and 
Figure 3. PGC-1α upregulates eNOS expression and limits hypertension-induced endothelial dysfunction. 
Human aortic endothelial cells (HAECs) were transfected or not with adenoviral (Ad) vectors containing  
β -galactosidase (Ctl) or PGC-1α for 24 h and assessed for (A) cGMP (N = 3), eNOS (B) mRNA (N = 3) and 
(C,D) protein; *P < 0.05 vs. Ctl. (E) Immunoblots for expression of the indicated proteins in MLECs from WT 
and PGC-1α EC TG mice (peNOS = phospho-Ser1177). Aortic segment contraction to phenylephrine (PE) 
in the absence (F) or presence (G) of 300 μ M LNAME (N = 5–7/group; *P < 0.05 vs. WT). (H) Systolic blood 
pressure in WT and PGC-1α EC TG mice treated with LNAME (0.5 g/L in drinking water for 7 days) with or 
without pressor doses of ATII for 7 days (N = 8; *P < 0.05). (I) Systolic blood pressure in response to ATII as a 
function of the indicated genotype (N = 16–18/grp).
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activation. In our studies, PGC-1α did not increase Akt activation or expression (Supplementary Figure 2A). 
Another mechanism of eNOS activation is through reactive oxygen species (ROS) as we and others have previ-
ously demonstrated that ROS can increase eNOS activity and expression18,19. However, we found decreased ROS 
production in endothelial cells from PGC-1α EC TG mice compared to WT mice (Supplementary Figure 2B). 
Thus, we turned our attention to well-known PGC-1α targets such as Estrogen Related Receptor α (ERRα and 
Peroxisome Proliferator-Activated Receptor γ (PPARγ ), that can modify eNOS expression or activity20. Forced 
expression of PGC-1α in HAECs produced no change in PPARγ expression, but a significant increase in ERRα 
(Fig. 4A). Endothelial cells harvested from WT mice treated with ATII demonstrated suppressed ERRα expres-
sion (Fig. 4B), reminiscent of the effect on PGC-1α (Fig. 1A). Furthermore, PGC-1α EC KO endothelial cells 
Figure 4. ERRα is required for PGC-1α dependent eNOS expression. (A) HAECs were transfected with 
adenoviral vectors expressing β -galactosidase (Ad-Ctl) or PGC-1α (Ad- PGC-1α ) and mRNA expression of 
the indicated genes determined by RT-PCR (N = 3, *P < 0.05). (B) ERRα mRNA in MLEC from mice treated 
with saline or ATII (1 mg/kg; 7days; N = 4/group). (C) ERRα mRNA in MLEC from Cre or PGC-1α EC KO 
mice (N = 3; *P < 0.05). (D) HUVEC were treated with adenovirus expressing irrelevant siRNA (siCtl) or 
ERRα siRNA (siERRα ) for 48 h followed by treatment with Ad-GFP or Ad-PGC-1α for 24 h. (E) MLEC from 
WT and PGC-1α EC TG mice were treated with adenovirus as in D (siCtl or siERRα ). Cell lysates were then 
immunoblotted for the indicated proteins. (F) Schematic of ATII-induced hypertension and PGC-1α in the 
endothelium.
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exhibit decreased ERRα expression (Fig. 4C), demonstrating that in endothelial cells, ERRα expression closely 
mimics the expression pattern of PGC-1α . We then investigated whether ERRα was necessary for the increased 
expression of eNOS. As ERRα has been shown to induce eNOS expression20, we used siRNA to knock down 
ERRα in HUVECs (Fig. 4D) and endothelial cells from our PGC-1α EC TG mice (Fig. 4E). In both of these cell 
types, PGC-1α mediated increases in eNOS expression were attenuated as demonstrated in summary (Fig. 4F).
Discussion
The data presented here indicate that PGC-1α expression plays an important role in the pathophysiology of 
angiotensin II-induced hypertension. Downregulation of PGC-1α was observed during ATII-infusion and loss 
of PGC-1α facilitated the development of endothelial cell dysfunction, whereas persistent endothelial PGC-1α 
expression attenuated the response to ATII. Of particular note, we identified a new role for PGC-1α in main-
taining eNOS expression: PGC-1α loss of function was associated with a reduction in eNOS expression and, 
conversely, PGC-1α gain of function increased basal eNOS expression. Furthermore, PGC-1α required ERRα to 
enhance eNOS expression. Collectively, these data indicate that PGC-1α is a key novel determinant of endothelial 
cell eNOS expression and, as a consequence, NO• bioactivity.
Although previous data has linked PGC-1α to nitric oxide dependent responses, generally the literature has 
been focused on the effects of NO• on PGC-1α , rather than vice versa as we describe here. For example, NO• 
has been shown to upregulate PGC-1α and stimulate mitochondrial biogenesis21. Likewise, caloric restriction, 
a state associated with increased longevity, causes mitochondrial biogenesis and PGC-1α upregulation in an 
eNOS-dependent manner22. The data presented here suggest a bidirectional relationship between PGC-1α and 
NO• , with the former being required to maintain normal eNOS expression in the endothelium.
Furthermore, we demonstrate that PGC-1α expression dictates endothelial function in the context of angi-
otensin II-induced hypertension, a disease model characterized by impaired NO• bioactivity and increased 
vascular ROS production23. With regard to the latter, there are several PGC-1α -dependent genes known to coor-
dinate antioxidant gene regulation, including SOD2, Prx3, Prx5, Trx 2, and catalase12. These data, combined 
with observations that PGC-1α protects the endothelium from ROS-mediated damage11,12,24, suggest that one 
potential mechanism for our observations may also be the antioxidant program promoted by PGC-1α . This idea 
is supported by observations that manipulation of vascular ROS scavenging are associated with improved NO• 
bioactivity and preservation of endothelial function25. However, the relative importance to the endothelium of 
PGC-1α action on ROS scavenging versus its effect on eNOS expression remains to be determined. Nevertheless, 
our data indicate that PGC-1α cannot significantly impact the consequences of ATII in the absence of eNOS.
In addition to ROS scavenging, PGC-1α expression has been implicated in protection from inflammation. For 
example, PGC-1α overexpression results in decreased endothelial inflammation in response to tumor necrosis 
factor-α 26 PGC-1α deficient mice bred onto the ApoE−/− background displayed increased inflammatory markers 
in plaques27. As ATII-induced hypertension is associated with a vascular inflammatory response with increased 
endothelial inflammatory gene expression28, one might speculate that endothelial PGC-1α manipulation may 
impact vascular inflammatory responses.
While, multiple studies in endothelial cells have demonstrated protection from ROS12,22, cell death29, and 
inflammation26, in conditions of high glucose, PGC-1α may have a detrimental effect and lead to impaired 
endothelial function. For instance, under diabetic conditions, PGC-1α overexpression led to decreased angio-
genesis, whereas PGC-1α loss of function improved endothelial angiogenesis30. Therefore, endothelial PGC-1α 
could potentially serve multiple contextual roles wherein conditions of hypertension, lead to improved eNOS bio-
availability, but in conditions of hyperglycemia, endothelial angiogenesis is impeded. Further investigation will 
be required for a complete picture as to how PGC-1α contributes to endothelial phenotype in health and disease.
The data presented here demonstrate a novel paradigm wherein PGC-1α induces expression of ERRα , which 
is then necessary to enhance eNOS expression (Fig. 4D,E). In our study, endothelial ERRα expression mirrored 
PGC-1α expression. Although it was known that the eNOS promoter contains an ERRα binding site20, we have 
now elucidated a functional connection to eNOS in vivo. The link between ERRα and PGC-1α is consistent with 
studies in mice lacking ERRα , that phenocopy the heart failure seen in PGC-1α knockout mice31. However, 
studies with endothelial-specific ERRα manipulation in vivo will be needed to further clarify its role in vascular 
function.
In summary, the work presented here links endothelial PGC-1α to NO• bioactivity via eNOS regulation. This 
indicates that endothelial PGC-1α expression may be an important determinant of vascular health (Fig. 4F) as it 
is protective from endothelial dysfunction in response to ATII. It will be of particular interest to determine if the 
molecular pathway described here impacts other critical processes involved in endothelial dysfunction, such as 
mitochondrial function, metabolism, and inflammation.
Methods
Materials. Antibodies: PGC-1α (Abcam); phospho-Ser1177 eNOS (Upstate Biotechnology); eNOS (BD 
Transduction); ERRα (Abcam); β -actin (Sigma). Micro-osmotic pumps were purchased from DURECT corpo-
ration (Cupertino, CA). Other chemicals were obtained from Sigma.
Generation of endothelial specific PGC-1α manipulation in mice. Human PGC-1α cDNA 
(Origene, Rockville, MD) was linearized and inserted into pBSmVELacZ (Obtained from Kenneth Walsh, Ph.D. 
Boston University, Boston, MA) to replace the LacZ open reading frame through the NotI site to produce human 
PGC-1α expression under the control of the mouse vascular endothelial cadherin promoter (VE-Cad; Fig. 2A). 
The resulting construct was microinjected into fertilized embryos harvested from C57BL/6 mice in the UMMS 
Transgenic Core to create the endothelial specific PGC-1α transgenic mouse line (PGC-1α EC TG). Genotyping 
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was performed with mouse tail DNA and primers of (ggctggtaccttggaactga) and (aatccgtcttcatccacagg). Two sep-
arate PGC-1α EC TG mouse lines were used for experiments. The PGC-1α EC TG mice were bred onto the back-
ground of eNOS−/− mice (Jackson Laboratory) to generate PGC1α -EC TG/eNOS−/− mice.
For the endothelial specific knockout line, the PGC-1α allele containing LoxP sites flanking exons 3–5 of the 
PGC-1α gene (PGC1αflox/flox)32 was obtained from Bruce Spiegelman (Harvard University) and bred with the 
Tie2-Cre mouse line on the C57 background. These endothelial-specific PGC-1α knockout mice (PGC-1α EC 
KO) were compared to Tie2-Cre mice (Cre). Approval for animal care and use for these experiments was granted 
by the Institutional Animal Care and Use Committee (IACUC) of the University of Massachusetts Medical School 
and the Ethics Committee of the University Hospital Mainz and all experiments were carried out in accordance 
with the guidelines from these institutions.
Cell culture. Primary cultures of human aortic endothelial cells (HAECs) or human umbilical vein endothe-
lial cells (HUVECs) were obtained from Lonza Group Ltd. (Switzerland) and used in experiments during pas-
sages 2–8. Cultures were maintained in EBM-2 media with supplements (Lonza). Primary cultures of rat aortic 
smooth muscle cells (RASMCs) were obtained from VEC Technologies (Rensselaer, NY, USA) and used in exper-
iments during passages 2–8. RASMC cultures were maintained in DMEM (Cellgro) that contained 10% fetal 
bovine serum, 500 IU/ml penicillin, and 500 IU/ml streptomycin. Mouse lung endothelial cells were prepared by 
immunoselection with anti-ICAM-2 antibody as previously described33. Adenovirus was used for both overex-
pression (24 h) and knockdown (48 h) of PGC-1α (kind gift from the laboratory of Bruce Spiegelman) and ERRα 
(kind gift from laboratory of Anastasia Kralli, Scripps Research Institute34). Control viruses (siCtl, LacZ, and 
GFP) from Vector BioLabs (Malvern, PA).
mRNA extraction and RT-PCR. RNA was extracted from endothelial cells or mice aorta using RNeasy 
mini kit (Qiagen) or Trizol tissue extraction. For mRNA expression analysis both TaqMan (Life Technologies) 
and SYBR Green (Bio-Rad) methods were used (Supplementary Table 1). The Δ Δ cycle threshold method was 
used for relative mRNA quantification and the gene expression was normalized to a housekeeping gene (TBP or 
HPRT).
Osmotic pump implantation. Mice were anesthetized with an intraperitoneal ketamine-xylazine mixture. 
Osmotic pumps (Alzet model 1007D) were implanted subcutaneously to allow infusion of ATII or vehicle (NaCl 
0.9%) at one of two rates for 7d: i) the suppressor rate of 0.5 mg · kg–1 · d–1 that does not significantly compromise 
endothelial function in wild type (WT) mice35 or a pressor rate of 1.0 mg · kg–1 · d–1 for 7 days which induces 
endothelial dysfunction and hypertension in WT mice5.
Blood pressure. Non-invasive determinations were performed in conscious mice by tail cuff sphygmoma-
nometer using BP-2000 pressure analysis system (Visitech Systems, Apex, NC) which we previously validated 
against telemetry monitoring35. The mice were trained daily for one week prior to recorded measurements. 
A minimum of 10 preliminary measurements with 20 actual measurements were performed in each session. 
Measurements were made at the same time each day to account for diurnal variation. Five consecutive daily meas-
urements were averaged for each of the groups. Where indicated, NG-nitro-L-arginine methyl ester (LNAME) 
was administered (0.5 g/L) in the drinking water for 7–14 days.
Western blot. The cell and tissue lysates were denatured with Laemmli sample buffer (Cell Signaling) and 
then resolved by SDS-PAGE followed by western blotting with antibodies as indicated. The protein bands were 
visualized using the AlphaImager© imaging system and bands quantified with Image J (NIH). Numbers below 
immunoblots represent densitometry relative to actin.
Tissue NO• measurement. Electron paramagnetic resonance spectrometry (EPR) was used to assess 
vascular NO• synthesis using colloid Fe(II)-diethyldithiocarbamate (Fe(DETC)2) as spin trap with an X-band 
table-top spectrometer MS200 (Magnettech, Berlin, Germany). The instrument settings were: 10 mW microwave 
power, 0.8 mT amplitude modulation, 100 kHz modulation frequency, 327 mT center field, 10 mT sweep width, 
60 s sweep time and 3 scans. Total NO• production was assessed by measurement amplitude of the characteristic 
triplet EPR signal and expressed in arbitrary units, AU/(mg dry weight × h)35.
Tissue cGMP. Tissue cGMP from aortas was measured as described33.
In vitro cGMP. Endothelial NO• bioactivity in culture was estimated as cGMP production in a RASMC 
reporter assay as previously described33.
Isometric Measurements of Aortic Function. Thoracic aortic rings (2 mm in length) were mounted on 
200 μ m pins in a 6-mL chamber vessel myograph (Danish Myo Technology; 610 M) with 1 g basal tension as pre-
viously described33. Aortic rings were subjected to concentration-response curves to increasing concentrations 
of phenylephrine (PE) and acetylcholine (Ach), the latter in vessels precontracted with a submaximal (70–80%) 
concentration of PE (10–7 M).
Statistics. Numerical data are presented as mean ± SE. Overall differences were analyzed using one-way or 
two-way ANOVA and tested with Tukey-Kramer Multiple-Comparison Test for determining differences between 
the means when more than two groups were compared. An independent t-test was used when only two groups 
were compared. In all tests, significance was accepted at P < 0.05.
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